Combination Chemotherapy in Treating Patients With Bladder Cancer
RadiCaL study results show adding bone-targeting radium-223 to cabozantinib does not improve symptomatic skeletal-related events, highlighting the value of current standard treatments to optimize bone health for patients with bone metastases. Results from the Alliance for Clinical Trials in Oncology’s Phase II RadiCaL trial (Alliance A031801), the first randomized study of a radiopharmaceutical in kidney…
A new randomized Alliance Foundation Trials (AFT) clinical study found that men with advanced prostate cancer taking the hormone therapy medication darolutamide had less cognitive decline compared to men taking enzalutamide. According to results from the ARACOG (AFT-47) phase II trial, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2026,…
The Alliance for Clinical Trials in Oncology and Alliance Foundation Trials will present a diverse portfolio of research at the 2026 ASCO Annual Meeting, taking place May 29-June 2 in Chicago, Illinois, spanning breast, gastrointestinal, genitourinary, thoracic, neuro-oncology, health outcomes, and data science. Collectively, these studies reflect the continued leadership of the Alliance in practice-changing clinical trials, translational biomarker…
Highlighting Alliance Progress and Impact in Research through News Reports At the Alliance for Clinical Trials in Oncology, we love sharing stories that show what’s happening in cancer research right now. Whether it’s a new clinical trial, a scientific breakthrough, or the work of one of our dedicated investigators, we want people to see the…
Categories
Alliance Committee
Browse by Year